

12/07/01

12-101-814

Rec'd PCT/PTO 07 DEC 2001

C7

PTO-1390 (Modified) (1-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 24025-501	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 10/009809	
INTERNATIONAL APPLICATION NO. PCT/IL00/00346		INTERNATIONAL FILING DATE 14 June 2000 (14.06.2000)		PRIORITY DATE CLAIMED 17 June 1999 (17.06.1999)	
TITLE OF INVENTION NOVEL ANTI-ALLERGIC AGENTS					
APPLICANT(S) FOR DO/EO/US EISENBERG, Ronit; RAZ, Tamar					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none">1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2))<ol style="list-style-type: none">a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).b. <input type="checkbox"/> has been communicated by the International Bureau.c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).<ol style="list-style-type: none">a. <input type="checkbox"/> is attached hereto.b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))<ol style="list-style-type: none">a. <input checked="" type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).b. <input type="checkbox"/> have been communicated by the International Bureau.c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.d. <input type="checkbox"/> have not been made and will not be made.8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).11. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409).12. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210).					
Items 13 to 20 below concern document(s) or information included:					
<ol style="list-style-type: none">13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.15. <input checked="" type="checkbox"/> A FIRST preliminary amendment.16. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.17. <input type="checkbox"/> A substitute specification.18. <input type="checkbox"/> A change of power of attorney and/or address letter.19. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.20. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).21. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).22. <input checked="" type="checkbox"/> Certificate of Mailing by Express Mail23. <input checked="" type="checkbox"/> Other items or information:					
Express Mail Label No. EL862267045US Filed on: 7 December 2001 (07.12.01)					

U.S. APPLICATION NO. IF KNOWN SEE 37 CFR

INTERNATIONAL APPLICATION NO.

ATTORNEY'S DOCKET NUMBER

10/009809

PCT/IL00/00346

24025-501

24. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

- ☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.00
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00
- ☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00
- ☒ International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$100.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).

\$0.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	51 - 20 =	31	x \$18.00	\$558.00
Independent claims	4 - 3 =	1	x \$80.00	\$80.00
Multiple Dependent Claims (check if applicable). <input type="checkbox"/>				\$0.00

TOTAL OF ABOVE CALCULATIONS =

\$738.00

☒ Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.

\$369.00

SUBTOTAL =

\$369.00

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).

\$0.00

TOTAL NATIONAL FEE =

\$369.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). ☐

\$0.00

TOTAL FEES ENCLOSED =

\$369.00

Amount to be:
refunded \$
charged \$

- a. ☒ A check in the amount of \$369.00 to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0311. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

ELRIFI, Ivor R.
Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C.
One Financial Center
Boston, Massachusetts 02111
United States of America

SIGNATURE

MARENBERG, Barry J.

NAME

40,715

REGISTRATION NUMBER

07 December 2001 (07.12.01)

DATE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INVENTORS:	Eisenberg <i>et al.</i>
UNITED STATES NATIONAL PHASE OF PCT INTERNATIONAL APPLICATION NO:	PCT/IL00/00346
INTERNATIONAL FILING DATE:	June 14, 2000
FOR:	NOVEL ANTI-ALLERGIC AGENTS

Boston, MA
December 07, 2001

Box PCT

Assistant Commissioner for Patents

PRELIMINARY AMENDMENT

Preliminary to examination, please amend the application as follows:

IN THE CLAIMS

Kindly add new claim 51 as follows:

51. (New) A method for promoting importation of a molecule into a cell of a subject *in vivo*, the method comprising the steps of:
- (a) attaching a leader sequence to the molecule, said leader sequence being a peptide having an amino acid sequence AAVALLPAVLLALLAP, to form a complex;
 - (b) administering said complex to the subject; and
 - (c) importing said complex into the cell through said leader sequence, such that the molecule is imported into the cell.

REMARKS


Applicant has added new claim 51, which was originally filed as claim 48 in the PCT international application, but which was inadvertently omitted from the set of amended claims submitted during Preliminary Examination. No new matter is submitted herewith by the addition of new claim 51.

INVENTORS: Grassy *et al.*
UNITED STATES
NATIONAL PHASE OF PCT/FR98/02909
PCT INTERNATIONAL
APPLICATION No:

CONCLUSION

Applicant requests that the Examiner enter these amendments and issue these claims.
If the Examiner has any further issues, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Barry J. Marenberg, Reg. No. 40,715
Attorneys for Applicants
c/o MINTZ LEVIN COHN FERRIS GLOVSKY
AND POPEO PC
One Financial Center
Boston, Massachusetts 02111
Telephone: (617) 542-6000
Telefax: (617) 542-2241

Express Mail Label No. EL862267045US
Date of Deposit: 07 December 2001 (07.12.01)

TRA 1601531v1

Express Mail Label No.: EL 955089157 US
Date of Deposit: April 26, 2002

10 APR 2002 2 6 APR 2002
Attorney Docket No. 24025-501 NATL.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Eisenberg and Raz
SERIAL NO: 10/009,809 INTERNATIONAL PCT/IL00/00346
APPLICATION NO :
I.A. FILING DATE: 06/14/2000 PRIORITY DATE : 06/17/1999
FOR: NOVEL ANTI-ALLERGIC AGENTS

April 26, 2002
Boston, Massachusetts

Box PCT
Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination of the above-identified patent application, please amend the application as set forth below and consider the following remarks.

In the Specification:

Please insert the Sequence Listing, pages 1-7, at the end of the specification.

REMARKS

Applicants submit a Sequence Listing for the nucleotide sequences disclosed in the specification, in compliance with the requirements for patent applications containing nucleotide sequences and/or amino acid sequence disclosures. 37 C.F.R. §§ 1.821-1.825.

CONCLUSION

Applicants respectfully submit that the present application complies with 37 C.F.R. §§ 1.821-1.825. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,



Ivor R. Elmi, Reg. No. 39,529
Barry J. Marenberg, Reg. No. 40,715
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

TRA 1661134v1

NOVEL ANTI-ALLERGIC AGENTSFIELD OF THE INVENTION

The present invention discloses novel anti-allergic agents, and in particular,
5 peptidic or peptidomimetic molecules, including at least a first segment which is
competent for cell penetration and a second segment which is able to reduce or abolish
mast cell degranulation, and in particular to reduce or abolish allergy mediators such as
histamine secretion from mast cells.

10 BACKGROUND OF THE INVENTION

Allergic diseases, including nasal allergy, asthma, urticaria and angioedema, are
among the most common diseases encountered by physicians in their clinical practice.
Allergy refers to certain diseases in which a wide spectrum of biologically active
substances, released from activated mast cells, cause tissue inflammation and organ
15 dysfunction. In essence, any allergic reaction may lead to tissue damage in one or more
target organs (see for example Lichtenstein 1993; full references are given in the list at the
end of the specification).

On the cellular level, mast cells are significant contributors to the allergic reaction
and are packed with 500 to 1000 granules in which the mediators of the inflammatory
20 reactions are stored. These include vasoactive mediators such as histamine, chemotactic
mediators and proteolytic enzymes. In addition, following the activation of mast cells, a
number of mediators are generated *de novo* and released. These include arachidonic acid
metabolites such as leukotrienes and prostaglandins and a number of multifunctional
cytokines. Mast cell derived factors also recruit and activate additional inflammatory
25 cells, such as eosinophils, neutrophils and mononuclear cells. Therefore, mast cell derived

mediators possess all the requisite properties to induce the symptoms of itching, swelling, coughing and choking that are associated with an allergic reaction (Bienenstock et al., 1987). These mediators are released in response to processes which occur through a number of different pathways within mast cells. Thus, therapeutic treatments for allergy and related inflammatory conditions must intervene at some point in the allergic pathway in order to be effective.

Current therapies against allergy include H₁ and H₂ blockers, which block the biological activities of histamine, and leukotriene antagonists, which block the biological activities of leukotrienes. Examples include chlorpheniramine, azatidine, ketotifen, loratidine, montelukast sodium and others. However, anti-histamines or anti-leukotrienes can not counteract the inflammatory reactions effected by the additional mediators released alongside histamine and leukotrienes. Therefore, these drugs cannot provide a reliable protection against allergy.

A better allergy treatment would block the secretory process by preventing mast cell degranulation. Drugs which are currently available for this purpose include hydrocortisone and disodium cromoglycate. However, disodium cromoglycate cannot inhibit all types of histamine secretion, and is not always completely effective. Steroids, on the other hand, are effective for blocking mast cell degranulation, but have many unacceptable side effects. Therefore, therapeutic agents which could prevent mast cell degranulation without significant side effects, and could thus prevent or significantly reduce the occurrence of clinical symptoms associated with allergy, such as neurogenic inflammation (see below for details), would be very useful for the treatment of allergy and related conditions.

Mast cell degranulation is a complex process involving at least two different pathways. Mast cells secrete their granular contents in a process of regulated exocytosis

(degranulation) by two major pathways, the IgE (immunoglobulin E) dependent pathway and the IgE independent pathway. The IgE dependent pathway is invoked in response to an immunological trigger, brought about by aggregation of the high affinity receptors ($F_{\epsilon}RI$) for IgE, which are present on the cell surface of mast cells. This response involves crosslinking of cell bound IgE antibodies by the corresponding antigens (allergens).

The IgE-independent or peptidergic pathway is invoked in response to a number of polycationic compounds, collectively known as the basic secretagogues of mast cells. These compounds include the synthetic compound 48/80, naturally occurring polyamines and positively charged peptides, such as the neurotransmitter substance P (Ennis et al., 1980; Sagi-Eisenberg 1993; Chahdi et al., 1998).

The ability of substance P to induce mast cell degranulation, together with the observed presence of mast cells clustered around nerve endings which contain substance P, implicate mast cells as the mediators of substance-P induced neurogenic inflammation (Foreman 1987a,b; Pearce et al., 1989). It is well established that in the skin and elsewhere neurogenic inflammation, through the release of neurotransmitters such as substance P, is a contributor to a variety of diseases such as acute urticaria, psychogenic asthma, interstitial cystitis, bowel diseases, migraines, multiple sclerosis and more (Reviewed by Theoharides 1996). In addition, this IgE independent pathway of degranulation can also be evoked by snake, bee and wasp venoms, bacterial toxins and certain drugs such as opiates.

Although the signal transduction pathways by which mast cell degranulation is activated are not yet fully resolved, a number of cellular events have been shown to occur after stimulation of the mast cells. These include activation of phospholipases such as PLC, PLD and PLA_2 , elevation of cytosolic Ca^{2+} and activation of serine and tyrosine kinases (reviewed by Sagi-Eisenberg 1993). Within these processes, however, the

involvement of GTP-binding proteins (G-proteins) is well established. For example, the introduction of nonhydrolyzable analogues of GTP, such as GTP- γ -S, into ATP⁻⁴ permeabilized mast cells, stimulates PLC activity and degranulation.

From these observations and other observations, the involvement of at least two different G-proteins, one involved in PLC and Ca²⁺ activation (G_P) and one directly regulating exocytosis (G_E), has been suggested (Gomperts et al., 1991; reviewed by Sagi-Eisenberg 1993). Indeed, it was subsequently demonstrated that basic secretagogues induce histamine secretion by interacting directly with G_E, a pertussis toxin-sensitive heterotrimeric G protein, in a receptor-independent manner (Aridor et al., 1990; Aridor & Sagi-Eisenberg 1990). This G-protein was subsequently identified as Gi₃, which appears to mediate the peptidergic pathway leading to exocytosis in mast cells. In particular, a synthetic peptide which corresponds to the C terminal sequence of G α i₃ (KNNLKECGLY) was able to inhibit histamine release when introduced, into permeabilized mast cells (Aridor et al., 1993).

However, the cell membrane is generally impermeable to most peptides. Therefore, the use of a peptide as a therapeutic agent, directed against an intracellular target, requires a special mechanism to enable the peptide to overcome the membrane permeability barrier.

One approach is based on the fusion of the selected peptide with a specific hydrophobic sequence, comprising the "h" region of a signal peptide sequence. Examples of such hydrophobic regions are the signal sequence of the Kaposi fibroblast growth factor (AAVALLPAVLLALLAP; Lin et al., 1995) and the signal sequence within human integrin β ₃ (VTVLALGALAGVGVG; reviewed by Hawiger 1997). Another approach is based on fusing the active anti-allergic peptide with a specific signal peptide sequence endowed with the membrane translocation properties of the homeodomain of

Antennapedia, a *Drosophila* transcription factor (RQPKIWFPNRRKPWKK; Prochiantz 1996).

Specific importation of biologically active molecules into cells by linking an importation-competent signal peptide to the molecule of interest was disclosed in U.S. Patent No. 5,807,746, although only *in vitro* studies were described, such that the signal peptide was not shown to function *in vivo*. The signal peptide causes the entire complex to be imported into the cell, where theoretically the biologically active molecule could then have its effect. Although such direct importation could serve to target the therapeutic compound, and could therefore prevent or substantially reduce side effects through non-targeted system activity, the efficacy of the complex within the cell may be limited, such that the biologically active molecule may have little or no effect once imported into the cell. The variables which may affect the efficacy of the biologically active molecule include the effect of linking the molecule to the signal peptide, which may result in an inactive complex; unpredictable effects of the entire complex within the cell; and even the inability of the entire complex to be imported into the cell, despite the presence of the signal peptide.

In addition, identifying a suitable biologically active molecule for treatment of allergy may also be difficult. For example, linking a non-peptide molecule, such as a known secretion-blocking compound, to a signal peptide is both difficult and may result in an unstable molecule. A peptide could be used as the secretion-blocking compound, but then such a peptide must be carefully selected and tested. Finally, the entire complex would require testing, particularly *in vivo*, since the ability to penetrate a cell in tissue culture does not necessarily predict the efficacy of the complex in a human or animal subject. U.S. Patent No. 5,807,746 therefore suffers from the drawback that only *in vitro* data is disclosed, such that the effect of the signaling peptides *in vivo*, alone or as part of a

complex, is not known. Thus, suitable, targeted, specific therapeutic agents for the treatment of allergy are not currently available and are potentially complex and difficult to develop.

There is therefore a need for, and it would be useful to have, a therapeutic agent for the treatment of allergy and related inflammatory conditions, which would block mast cell degranulation and hence the release of histamine, but which would be specifically targeted to the degranulation pathway and which would therefore have few side effects.

SUMMARY OF THE INVENTION

The present invention discloses a therapeutic complex for the specific, direct and targeted treatment of allergies and related inflammatory conditions, which includes at least a first segment which is competent for the importation of the complex into mast cells, and a second segment which is able to block or significantly reduce mast cell degranulation and hence the release of histamine. By way of a non-limitative example, the first segment could include a signal peptide which is competent for the importation of the complex into mast cells, while the second segment could include a biologically active molecule, such as a peptide which is able to block the G protein-mediated contribution to the mast cell degranulation process.

According to the present invention, there is provided an anti-allergic complex, comprising a molecule having at least a first segment competent for importation of the molecule into mast cells, and a second segment for having an anti-allergic effect within the mast cells, the first segment being joined to the second segment through a linker.

Preferably, the second segment provides the anti-allergic effect by at least significantly reducing degranulation of the mast cells. More preferably, the second segment is selected from the group consisting of a peptide, a peptidomimetic, a

polypeptide, a protein, a nucleic acid, a carbohydrate, a lipid, and a glycolipid. Most preferably, the second segment is a peptide or a peptidomimetic. Also most preferably, the first segment is a peptide or a peptidomimetic.

According to a preferred embodiment of the present invention, the linker is a
5 covalent bond. Preferably, the covalent bond is a peptide bond. More preferably, the molecule is a peptide taken from the C terminal sequence of G α i₃. Most preferably, the peptide has an amino acid sequence AAVALLPAVLLALLAPKNNLKECGLY.

According to another particularly preferred embodiment of the present invention,
the molecule is a peptide having an amino acid sequence
10 AAVALLPAVLLALLAPKENLKDCGLF.

According to another embodiment of the present invention, there is provided a composition for treating an allergic condition in a subject, comprising a pharmaceutically effective amount of a therapeutic agent for administering to the subject, the therapeutic agent comprising a molecule having at least a first segment competent for importation of
15 the molecule into mast cells, and a second segment having an anti-allergic effect within the mast cells, the first segment being joined to the second segment through a linker.

Preferably, the allergic condition is selected from the group consisting of nasal allergy, an allergic reaction in an eye of the subject, an allergic reaction in the skin of the subject, acute urticaria, psoriasis, psychogenic or allergic asthma, interstitial cystitis,
20 bowel diseases, migraines, and multiple sclerosis. More preferably, the therapeutic agent is administered by topical administration. Most preferably, the topical administration is to the skin of the subject.

According to another preferred embodiment of the present invention, the therapeutic agent is administered by inhalation or intranasally. Alternatively and
25 preferably, the therapeutic agent is administered orally or systemically via parenteral

routes, including in depot form, or by any other suitable route of administration.

According to a currently more preferred embodiment of the present invention, the molecule comprises a peptide having an amino acid sequence selected from the group consisting of :

- 5 i) AAVALLPAVLLALLAPKNNLKECGLY;
 - ii) AAVALLPAVLLALLAPKENLKDCGLF;
 - iii) Succinyl-AAVALLPAVLLALLAPKNNLKECGLY;
 - iv) Cyclic- AAVALLPAVLLALLAPKNNLKECGLY;
- and mixtures, functional homologs or derivatives thereof.

- 10 More preferably the therapeutic agent further comprises a second molecule, the second molecule comprising a peptide having an amino acid sequence

According to still another embodiment of the present invention, there is provided a method for treating an allergic condition in a subject, comprising the step of administering a pharmaceutically effective amount of a therapeutic agent to the subject, the therapeutic agent comprising a molecule having at least a first segment competent for importation of the molecule into mast cells, and a second segment for having an anti-allergic effect within the mast cells, the first segment being joined to the second segment through a linker.

- 15 According to yet another embodiment of the present invention, there is provided a method for promoting importation of a molecule into a cell of a subject *in vivo*, the method comprising the steps of:

- (a) attaching a leader sequence to the molecule, the leader sequence being a peptide having an amino acid sequence AAVALLPAVLLALLAP, to form a complex; (b) administering the complex to the subject; and (c) importing the complex into the cell
- 20 through the leader sequence, such that the molecule is imported into the cell.
- 25

Hereinafter, the term "biologically active" refers to molecules, or complexes thereof, which are capable of exerting an effect in a biological system. Hereinafter, the term "fragment" refers to a portion of a molecule or a complex thereof, in which the portion includes substantially less than the entirety of the molecule or the complex thereof.

Hereinafter, the term "amino acid" refers to both natural and synthetic molecules which are capable of forming a peptide bond with another such molecule. Hereinafter, the term "natural amino acid" refers to all naturally occurring amino acids, including both regular and non-regular natural amino acids. Hereinafter, the term "regular natural amino acid" refers to those alpha amino acids which are normally used as components of a protein. Hereinafter, the term "non-regular natural amino acid" refers to naturally occurring amino acids, produced by mammalian or non-mammalian eukaryotes, or by prokaryotes, which are not usually used as a component of a protein by eukaryotes or prokaryotes. Hereinafter, the term "synthetic amino acid" refers to all molecules which are artificially produced and which do not occur naturally in eukaryotes or prokaryotes, but which fulfill the required characteristics of an amino acid as defined above.

Hereinafter, the term "peptide" includes a chain of a sequence of amino acids, whether natural, synthetic or recombinant, wherein said amino acids are linked by peptide bonds.

Hereinafter, the term "peptidomimetic" includes both peptide analogues and mimetics having substantially similar or identical functionality thereof, including analogues having synthetic and natural amino acids, wherein the peptide bonds may be replaced by other covalent linkages.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention is herein described, by way of example only, with reference to the

accompanying drawings, wherein:

Figure 1 is a graph of the effect of different peptides on histamine secretion.

Figure 2 is a graph of the dose effect of compound 48/80 induced histamine release from intact mast cells.

5 Figure 3 is a graph of the inhibitory effect of peptides 1 and 4 on histamine secretion.

Figure 4 is a graph of the inhibitory effect of peptides 2 and 5 on histamine secretion.

Figure 5: Inhibitory effect of peptide 2 on histamine secretion.

10 Figure 6: Inhibitory effect of peptide 2 on substance P induced histamine secretion.

Figure 7: Blocking effect of peptide 5 on histamine secretion.

Figure 8: Effect of different peptides on histamine secretion.

15 Figure 9: Effect of peptide 20 (A) and peptide 21 (B) on histamine secretion, induced by compound 48/80.

Figure 10: Effect of succinylated peptide 2 (2-Suc) on histamine secretion.

Figure 11: A computerized model demonstrating 3D structure of the C-terminus sequence of Peptide 2 - KNNLKECGLY (A) and peptide 5m - KNNLKDCGLF (B).

Figure 12: Effect of peptide 2-Cyc on histamine secretion.

20 Figure 13: Effect of peptide 2 and peptide 2-Suc on IgE Induced histamine secretion.

Fig 14: Rat Skin Test demonstrates the wheals that developed as a result of intradermal injection of Vehicle (B,D,F) or compound 48/80 (A,C,E), after intradermal injection of vehicle (A,B) or two different concentrations of Peptide 2 (C,D and E,F).

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention discloses a therapeutic complex for the specific, direct and targeted treatment of allergies and related inflammatory conditions, which comprises

5 molecules having at least a first segment which is competent for the importation of the complex into mast cells, and a second segment which is able to block or significantly reduce mast cell degranulation and hence the release of histamine. The first segment is connected to the second segment through a linker.

The first segment is a molecule, preferably a peptide, and more preferably a signal

10 peptide. A signal peptide is a peptide which is capable of penetrating through the cell membrane, to permit the exportation and/or importation of proteins or peptides. As used herein, suitable signal peptides are those which are competent for the importation of proteins, peptides or other molecules into the cell. Such signal peptides generally feature approximately 10-50 amino acids, of which a majority are typically hydrophobic, such

15 that these peptides have a hydrophobic, lipid-soluble portion. Preferably, signal peptides are also selected according to the type of cell into which the complex is to be imported, such that signal peptides produced by a particular cell type, or which are derived from peptides and/or proteins produced by that cell type, can be used to import the complex into cells of that type. Examples of such signal peptides are described above and are also

20 disclosed in U.S. Patent No. 5,807,746, incorporated by reference as if fully set forth herein for the teachings regarding signal peptides.

The second segment is a molecule which has an anti-allergic effect, preferably by preventing mast cell degranulation, and hence the release of histamine from these mast cells. The molecule is preferably a peptide, and more preferably a peptide derived from

25 the C terminal sequence of $G\alpha i_3$, which appears to mediate the peptidergic pathway

leading to exocytosis in mast cells. Alternatively, the second segment is selected from the group consisting of a polypeptide, a protein, a nucleic acid, a carbohydrate, a lipid, and a glycolipid.

The linker which connects the first segment to the second segment is preferably a covalent bond, and more preferably a peptide bond if at least one of the first and second segments is a peptide. A non-peptidic covalent bond could be formed by methods which are known in the art, such as for example cross-linking the first and the second segments with a cross-linking reagent, such as glutaraldehyde for example. It will be appreciated by the artisan that the linker which connects the first segment to the second segment may also include a molecular spacer segment which may be either peptidic or non-peptidic in nature.

The present invention also discloses methods for treating allergies. Hereinafter, the term "treatment" includes both the prevention of the allergic condition, as well as the substantial reduction or elimination of allergic symptoms. Allergic conditions for which the therapeutic agents of the present invention are useful include, but are not limited to, nasal allergy, irritation or allergic reactions in the eyes, allergic reactions in the skin including any type of allergen-induced rash or other skin irritation or inflammation, acute urticaria, psoriasis, psychogenic or allergic asthma, interstitial cystitis, bowel diseases, migraines, and multiple sclerosis.

Such treatment may be performed topically, for example for skin allergies and allergic reactions, including but not limited to, contact dermatitis in reaction to skin contact with an allergen; reactions to insect bites and stings; and skin reactions to systemic allergens, such as hives appearing after a food substance has been ingested by the subject. Alternatively and/or additionally, such treatment may be performed by systemic administration of the therapeutic complex. A preferred route of administration is

oral, but alternative routes of administration include, but are not limited to, intranasal, intraocular, sub-cutaneous and parenteral administration. Other routes of administration, and suitable pharmaceutical formulations thereof, are described in greater detail below.

As noted previously, in the currently most preferred embodiments of the present invention, the first and the second segments are both peptides which are joined with a peptide bond.

According to the principles of the present invention, novel peptides, designated as peptides 1-6, were designed and synthesized to include distinct importation competent signal peptides as a first segment at the N-terminus (underlined) and the C-terminal sequences of Gα_{i3} or Gα_t at the C-terminus as a second segment. In the following list the non-underlined part is Gα_{i3} for peptides 1-3, and Gα_t for peptides 4-6:

1. VTVLALGALAGVGVGKNNLKECGLY
2. AAVALLPAVLLALLAPKNNLKECGLY
3. ROPKIWFNRRKPWKKNNLKECGLY
4. VTVLALGALAGVGVGKENLKDCGLF
5. AAVALLPAVLLALLAPKE NLKDCGLF
6. ROPKIWFNRRKPWKKKENLKDCGLF

These peptides were then examined *in-vitro* for their ability to block compound 48/80 induced histamine secretion from purified rat peritoneal mast cells (Aridor *et al.*, 1993). Peptides 2 and 5 were demonstrated as blockers of compound 48/80 induced histamine secretion from mast cells in a dose response effect. Peptide 2 was more potent than peptide 5, however when applied together both peptides showed a synergistic effect for inhibiting histamine release. Peptides 1,3,4, and 6 showed no inhibition.

Peptides 2 and 5, and their homologues or structurally similar related compounds, could therefore be useful for non-immunological (IgE-independent) allergies, in which

mast cell degranulation is mediated through the IgE-independent pathway from which the second segment of the above peptides was taken. Examples of such allergies include but are not limited to neurogenic inflammation in the skin and elsewhere, including but not limited to, acute urticaria, psoriasis, psychogenic asthma, interstitial cystitis, bowel diseases, migraines, and multiple sclerosis. In addition, the leader sequence (first segment) of peptides 2 and 5 could also be useful for the importation of a molecule into the cell of a subject *in vivo*, as such an effect had not been previously demonstrated in the background art.

EXAMPLE 1 TESTING OF PEPTIDES 1-6 *IN VITRO*

Peptides 1-6 of the present invention, as described above, were tested *in vitro* for their ability to block histamine secretion from mast cells. Rat peritoneal mast cells were chosen as the experimental model, since it was previously shown that both rat peritoneal and human skin mast cells release histamine in response to substance P by an IgE-independent mechanism (Devillier et al., 1986; Foreman 1987a,b; Columbo et al., 1996). It was also demonstrated that the same peptidergic pathway is involved in both rat peritoneal and human cutaneous mast cells (Mousli et al., 1994; Emadi-Khiav et al., 1995).

Compound 48/80 was chosen as the allergen since it is one of the polycationic compounds, collectively known as the basic secretagogues of mast cells. Compound 48/80 has been shown to induce degranulation of human mast cells. In particular, it is very active on skin mast cells. Compound 48/80 has been used as a diagnostic agent *in vivo* to assess the release ability of human mast cells, to determine the effectiveness of drugs against chronic urticaria and to study itch and flare responses in atopic dermatitis

(Kivity et al., 1988; Goldberg et al., 1991). Therefore inhibition of compound 48/80 induced histamine release is applicable and relevant to prevention of allergy induced by other basic secretagogues such as substance P, snake, bee and wasp venoms, bacterial toxins and certain drugs such as opiates.

5 The ability of each of peptides 1-6 to inhibit mast cell degranulation, when induced by compound 48/80, was then tested. The experimental method was as follows.

MATERIALS AND METHODS

Peptide synthesis

10 Peptides were synthesized by IMI (Institute for Research and Development Ltd., Haifa, Israel). Peptides were synthesized by the solid phase methodology and supplied at > 95% purity. The correct composition and purity of the peptides were verified by HPLC, mass spectrometry and amino acid analysis. Peptides stock solutions (5 mg/ml in 10% dimethylsulfoxide (DMSO) in H₂O) were kept at -20 °C.

Isolation and purification of mast cells

15 Mast cells from the peritoneal cavity of C.R rats were isolated in Tyrode buffer (137 mM NaCl, 2.7 mM KCl, 1 mM MgCl₂, 0.4 mM NaH₂PO₄, 20 mM Hepes, 1.0 mM CaCl₂, 5.6 mM glucose, 1 mg/ml BSA, pH 7.2) and purified over a Ficoll gradient. A suspension of washed peritoneal cells was placed over a cushion of 30% Ficoll 400
20 (Pharmacia Biotech.) in buffered Saline containing 0.1% BSA, and centrifuged at 150xg for 15 min. The purity of mast cells recovered from the bottom of the tube was > 90%, as assessed by toluidine blue staining.

Triggering histamine secretion from intact cells

25 Purified mast cells (duplicated of 10⁵ cells/0.5ml) were incubated in Tyrode buffer

with buffer or with desired concentrations of the indicated peptide for 2 h. at 37°C.

Histamine secretion was subsequently stimulated by the indicated concentration of

compound 48/80 (Sigma) dissolved in Tyrode buffer. Incubation with compound 48/80

was carried out for 20 min. at 37°C. The reaction was terminated by placing the tubes on

ice. The cells were sedimented by centrifugation at 150xg for 5 min. and the supernatants

were collected. The amount of histamine release was determined as previously described

(Aridor et al.,1990). Briefly, cell pellets were lysed using 0.1N NaOH and the volume of

each sample was adjusted to 0.5 ml by H₂O. Histamine content was assayed using the o-

phthalaldehyde (OPT) fluorimetric method (Shore et al., 1959). Aliquots of 0.4 ml from the

supernatants and cell lysates were incubated with 1.6 ml H₂O, 0.4 ml 1N NaOH and 0.1

ml of 10 mg/ml OPT in methanol, for 4 min. at room temperature. The reaction was

terminated by the addition of 0.2 ml 3N HCl. Samples were centrifuged at 150xg for 5

min. and 0.2 ml samples were transferred to a 96 well plate. The histamine

spectrofluorometric assay was run in microplates using a microplates reader (FL-600,

Biotek instruments Winooski, VT, USA). Samples were excited by light at 340nm and

read at 440nm. Histamine release was calculated as the percentage of total histamine

content (supernatant / pellet + supernatant) in each sample. Each data point represents the

average of duplicate measurements. The spontaneously released histamine was subtracted.

Statistical analysis and plotting were done with Excel® (Microsoft Ltd., Washington,

USA).

Induction of Histamine Secretion by Substance P

The induction of histamine secretion was performed by 50 µM of the

physiological basic secretagogue substance P, and thus mimics histamine release in vivo.

In these experiments, mast cells were incubated with increasing concentrations of peptide

2 for 2 h. at 37 °C. Following the two hour incubation period, histamine secretion was stimulated by 5 µl of substance-P at a final concentration of 50 µM. Histamine release was determined as previously described, and is presented as percentage of the maximal response, which corresponds to a known percentage of the total cellular histamine content.

RESULTS

As demonstrated in Figure 1, peptides 1 and 4 (which both include the leader motif of the signal sequence within human integrin β_3 linked to the C-terminal sequences of $G\alpha_i3$ or $G\alpha_t$, respectively) exerted hardly any stimulatory effect on histamine secretion at a concentration range of up to 400 µg/ml of the peptide (Figure 1A). Similar results were obtained with peptides 2 and 5 (which both include the leader motif of the signal sequence of the Kaposi fibroblast growth factor linked to the C-terminal sequences of $G\alpha_i3$ or $G\alpha_t$, respectively) at a concentration range of up to 600 µg/ml of the peptide (Figure 1B). In contrast, peptides 3 and 6 (which both include the leader motif of the homeodomain of a *Drosophila* transcription factor linked to the C-terminal sequences of $G\alpha_i3$ or $G\alpha_t$, respectively) induced histamine secretion from mast cells in a concentration dependent manner (Figure 1C). These results suggest that peptides containing the h region of a signal peptide sequence of either the signal sequence of the Kaposi fibroblast growth factor or the signal sequence within human integrin β_3 , can serve as potential inhibitors of mast cells exocytosis, as they do not exert side effects of effecting histamine secretion. In contrast, peptides including the leader motif of the homeodomain of the *Drosophila* transcription factor induce side effects of histamine secretion, and therefore can not serve as potential inhibitors of mast cells exocytosis.

In order to investigate the ability of peptides 1, 2, 4 and 5, which did not exert side effects on mast cells *in vitro*, to block allergen-induced exocytosis, these peptides were examined for their ability to block compound 48/80 induced histamine secretion from intact mast cells *in vitro*.

5 First, the effect of compound 48/80 on exocytosis from intact mast cells was determined. A calibration curve is demonstrated in Figure 2, displaying a dose response of histamine release induced by compound 48/80. Histamine release was determined and is presented as the net secretion, that is % of the total cellular histamine following subtraction of the spontaneously released histamine. Half-maximal release was obtained
10 at 0.1 $\mu\text{g/ml}$ while maximal release was obtained at 1-10 $\mu\text{g/ml}$. Accordingly, in order to analyze the potential of each peptide to block histamine secretion, histamine secretion was induced with 5 $\mu\text{g/ml}$ compound 48/80, a concentration that induces a maximal histamine release, while the cells were incubated in the presence of increasing concentrations of each peptide.

15 Peptides 1 and 4 (which include the leader motif of the signal sequence within human integrin β_3 and the C-terminal sequences of $\text{G}\alpha\text{i}_3$ or $\text{G}\alpha\text{t}$, respectively) exerted hardly any blocking effect on histamine secretion that was induced by compound 48/80, at a concentration range of up to 400 $\mu\text{g/ml}$ of the peptide (Figure 3). Applying both peptides simultaneously in a concentration range of even up to 600 $\mu\text{g/ml}$ did not reveal
20 any synergistic effect. Thus, peptides 1 or 4, which include the leader motif of the signal sequence within human integrin β_3 , although exerting no side effects on mast cells in our *in vitro* system, do not block histamine secretion, and hence cannot serve as potential inhibitors of mast cells exocytosis.

On the other hand, peptides 2 and 5 (which both include the leader motif of the

signal sequence of the Kaposi fibroblast growth factor linked to the C-terminal sequences of $\text{G}\alpha_{i3}$ or $\text{G}\alpha_t$, respectively) exerted inhibition of histamine secretion that was induced by compound 48/80 (Figure 4). Peptide 5 demonstrated very moderate inhibition of up to 16% of the maximal response at a concentration of 800 $\mu\text{g/ml}$. Peptide 2 was more potent and inhibited by 25% the maximal response, at a concentration of 600 $\mu\text{g/ml}$. Applying both peptides simultaneously revealed a synergistic effect causing more extensive inhibition of histamine secretion at a concentration dependent manner (Inhibition of 25 %, 38% and 45% of the maximal response at concentrations of 400, 600 and 800 $\mu\text{g/ml}$, respectively). Thus, peptides 2 and 5 can serve as potential inhibitors of mast cell exocytosis, while exerting no side effects in this experimental system.

In order to examine further the ability of peptide 2 to serve as a blocker of histamine release, induction of histamine secretion was performed by 0.1 $\mu\text{g/ml}$ compound 48/80, a concentration that was demonstrated previously to cause half-maximal release of histamine (Figure 2), and thus mimics histamine release *in vivo* occurring following exposure to substance-P or other physiological basic secretagogues. As shown in Figure 5, the results demonstrate that peptide 2 exerted inhibition of histamine secretion induced by 0.1 $\mu\text{g/ml}$ of compound 48/80. This inhibition was dose dependent with maximal inhibition of 84% achieved at a concentration of 600 $\mu\text{g/ml}$ peptide.

Figure 6 shows that peptide 2 also exerted inhibition of histamine secretion induced by substance P. This inhibition was dose dependent with maximal inhibition of 67% achieved at a concentration of 400 $\mu\text{g/ml}$ peptide. Thus, peptide 2 has the potential to fully block histamine release from mast cells induced by physiological concentrations of basic secretagogues. This peptide may thus provide a unique and effective means to block mast cell exocytosis that leads to the allergic reaction.

In order to examine further the ability of peptide 5 to serve as a blocker of histamine release, mast cells were incubated with different concentrations of peptide 5, followed by induction of histamine secretion by 0.1 µg/ml compound 48/80. As shown in Figure 7, the results demonstrate that peptide 5 exerted inhibition of histamine secretion induced by 0.1 µg/ml of compound 48/80. This inhibition was dose dependent with maximal inhibition of 70% achieved at a concentration of 600 µg/ml peptide.

EXAMPLE 2

PEPTIDE MODIFICATIONS

The results described in Example 1 above demonstrated that both peptide 2 and peptide 5 have the ability to block mast cell degranulation, with peptide 2 demonstrating higher efficacy as compared to peptide 5. Peptide 2 had the highest inhibition of histamine release demonstrated, with 84% inhibition, as opposed to 70% for peptide 5.

Several point mutations and biochemical modifications were performed in each peptide, in order to improve peptide solubility and efficacy, as well as to investigate structure/function relationships.

The first such mutation is a point mutation in peptide 5. Specifically, in peptide 5, the glutamic acid in position 18 was replaced by asparagine, to form peptide 5-modified (Peptide 5m – AAVALLPAVLLALLAPKNNLKDCGLF). In this peptide the last 10 amino acids are homologous to the C-terminal sequence of $G\alpha i_2$.

Next, in an attempt to improve peptide solubility, a lysine residue was added to the N-terminus of the peptides 2 and 5, to form 2 new sequences:

Peptide 12: KAAVALLPAVLLALLAPKNNLKDCGLF

Peptide 13: KAAVALLPAVLLALLAPKNNLKECGLY

Amino acids were then deleted, in order to shorten peptides 2 and 5, by removing 3 amino acids from positions 17-19 to form 2 new sequences, respectively:

Peptide 20: AAVALLPAVLLALLAPLKECGLY

Peptide 21: AAVALLPAVLLALLAPLKDCGLF

Also, various point mutations were made in peptide 2. First, cysteine residue was replaced, in an attempt to improve peptide efficacy and to avoid possible oxidation of the peptide. Specifically, the cysteine residue in position 23 of peptide 2 was replaced by serine, to form the following sequence:

Peptide 25: AAVALLPAVLLALLAPKNNLKESGLY

An additional approach to improve peptide solubility involved changing the configuration of the peptide N-terminus to D/L configuration, thus forming the sequence:

Peptide 2 D/L: H- (D, L)-A- (D, L)-A-VALLPAVLLALLAPKNNLKESGLY

Also, in order to improve peptide solubility, a succinyl residue was added to the N-terminus of the peptides, to form 2 new sequences:

Peptide 2-Succinylated(2-Suc):

Succinyl-AAVALLPAVLLALLAPKNNLKESGLY

Peptide 5-Succinylated (5-Suc):

Succinyl-AAVALLPAVLLALLAPKENLKDCGLF

All of these peptides were tested as previously described in Example 1.

RESULTS

Certain specific modifications of the peptides 2 and 5 (previously exhibiting the desired anti-allergic activity), rather than preventing or abolishing histamine secretion,

actually potentiated such secretion, as shown in Figure 8. These peptides include peptide 5m (which contains a homologue sequence to the C-terminus of $G\alpha_{i2}$, Figure 8A); peptides 12 and 13 (which contain a lysine residue at the N-terminus of the peptide; Figures 8B,C respectively); peptide 25 (which contains a serine residue at position 23 instead of a cysteine; Figures 8F); peptide 2-D/L (containing an alternative D/L configuration at the N-terminus of the peptide; Figure 8G); and peptide 5-Suc (which contains a succinyl residue at the N-terminus of the peptide; Figure 8I). Since these peptides induced histamine secretion from mast cells in a concentration dependent manner, without the presence of any additional allergen, these peptides actually cause allergic side effects and cannot serve as potential inhibitors of mast cell exocytosis.

With regard to the remaining peptides, peptides 20 and 2-Suc did not induce histamine secretion from mast cells (demonstrated in Figure 8 D,H, respectively). Peptide 21 induced some histamine secretion at higher doses of 400 and 600 $\mu\text{g/ml}$ (Figure 8E).

In order to investigate the ability of these peptides to block allergen-induced exocytosis, the peptides were examined for their ability to block compound 48/80 induced histamine secretion from intact mast cells *in vitro*. Mast cells were incubated with different concentrations of each peptide, followed by induction of histamine secretion by compound 48/80.

As shown, peptides 20 and 21 did not block histamine secretion as induced by compound 48/80 (Figure 9). These results suggest that deletion of 3 amino acids at positions 17-19 causes the loss of desired activity, and such that these deleted peptides therefore can not serve as potential inhibitors of mast cells exocytosis in these conditions. However, as demonstrated in Figure 10, peptide 2-Suc did block histamine secretion that was induced by compound 48/80. These results illustrate that peptide 2-Suc, which is more soluble in the assay medium, as compared to peptide 2, had no stimulatory effect on

mast cells while exerting inhibition of histamine secretion induced by compound 48/80.

This inhibition was dose dependent with maximal inhibition of 80% achieved at a concentration of 600 $\mu\text{g/ml}$ peptide.

Thus, these results demonstrate that peptide 2 (which includes the leader motif of the signal sequence of the Kaposi fibroblast growth factor linked to the C-terminal sequences of $\text{G}\alpha\text{i}_3$) is a potent inhibitor of mast cell degranulation, *in vitro*. Addition of a succinyl residue to the N-terminus of this peptide increased both its solubility and its efficacy. Both peptides blocked compound 48/80 induced histamine secretion from mast cells in a dose dependent manner, where maximal inhibition was received at 600 $\mu\text{g/ml}$.

The IC_{50} decreased from 400 $\mu\text{g/ml}$ (Peptide 2; Figure 5) to 200 $\mu\text{g/ml}$ (Peptide 2-Suc; Figure 10). Without wishing to be limited by a single hypothesis, the apparent increase in potency may be caused by the increased solubility of the succinylated form.

Peptides 2 and 2-Suc were also tested *in vitro* for their ability to block histamine secretion from rat peritoneal mast cells, in response to the IgE-dependent mechanism. The IgE dependent pathway is activated in response to an immunological trigger, brought about by aggregation of the high affinity receptors ($\text{F}_\epsilon\text{cRI}$) for IgE, which are present on the cell surface of mast cells. This response involves crosslinking of cell bound IgE antibodies by the corresponding antigens (allergens).

Isolated, purified mast cells were sensitized in the presence of a monoclonal DNP-specific IgE antibody ($1\mu\text{g}/10^6$ cells) for 1 hour at 37°C . The cells were washed 3 times and incubated for 2 hours with different concentrations of each peptide, followed by triggering with the antigen DNP-BSA (100 ng/ml) in the presence of Brain Extract (0.1mg/ml), for 20 min. at 37°C . Placing the tubes in ice terminated the reaction. The amount of histamine released from the cells was monitored.

The results demonstrate that both peptides -2 and 2-Suc effectively block histamine secretion from isolated and purified rat mast, activated by an immunological trigger. Peptide 2-Suc, as a presumably more soluble version of peptide 2, is more effective as an inhibitor of histamine secretion, demonstrating 90% inhibition at a concentration of 600 µg/ml (Figure 13).

EXAMPLE 3 PEPTIDE CYCLIZATION

Based on the results of Examples 1 and 2, similar peptide sequences, differing only in one or two amino acids, may be significantly distinct from each other in their activity and the response they induce in mast cells.

In order to establish possible structure/function relationships, and to demonstrate the 3D structure of the active sequence of the molecule, as compared to less active sequences, computerized modeling was performed on the C-terminus of peptides, containing different amino acid sequences that demonstrate various levels of activity. The results illustrate a favored cyclic structure (by energy requirements, assuming hydrophobic or hydrophilic environment) of the C-terminus of Peptide 2, as compared to an open structure of peptide 5m, which induces side effects of histamine secretion from the cells (Figure 11).


In light of the aforementioned results, a cyclic form of peptide 2 was synthesized, forming a cyclization between the side chain of Lysine at position 17 and the C-terminus of the peptide:



The results demonstrate that peptide 2-Cyc exerted only minor side effects of histamine secretion in mast cells *in vitro*, (at a concentration of 100 µg/ml). Yet, peptide 2-Cyc demonstrated only limited potential to block compound 48/80 induced histamine secretion, and only at very high peptide concentrations (see figure 12). However, the cyclic peptide also had a very poor solubility in the buffer (Tyrode) used in the assay. Therefore, the low potency may be related to its low solubility.

Table 1 summarizes the results obtained in the *in vitro* system, demonstrating different responses of mast cells to the various peptides.

Table 1: Summary of *in vitro* results – histamine secretion from isolated mast cells, following treatment with different peptides

Peptide	Sequence	Secretagogue*	Inhibitor**	Remarks
2	AAVALLPAVLLALLAPKNNLKECGLY	-	++	Intermediate Solubility
2-Suc	Succinyl-AAVALLPAVLLALLAPKNNLKECGLY	-	+++	Good solubility
2-Cyc	AAVALLPAVLLALLAPKNNLKECGLY <div style="text-align: center;">  <p>ε-NH</p> </div>	-/+	+	Poor solubility
5	AAVALLPAVLLALLAPKENLKDCLF	-	++	Intermediate Solubility
5m	AAVALLPAVLLALLAPKNNLKDCGLF	+	-	
5-Suc	Succinyl-AAVALLPAVLLALLAPKENLKDCLF	+	-	
12	KAVALLPVLLALLAPKNNLKDCGLF	+	-	
13	KAVALLPVLLALLAPKNNLKECGLY	+	-	
20	AAVALLPAVLLALLAPLKECGLY	-	-	
21	AAVALLPAVLLALLAPLKDCGLF	-/+	-	
25	AAVALLPAVLLALLAPKNNLKESGLY	+	-	
2 D/L	H- (D, L)-A- (D, L)-A- VALLPAVLLALLAPKNNLKECGLY	+	-	

* Histamine secretion following incubation of mast cell with different

5 concentrations of each peptide: - No side effect of histamine secretion. + Peptide that induce histamine secretion (Secretagogue).

10 ** Degree of Inhibition of histamine secretion from mast cells, followed by incubation with different concentrations of each peptide and induction of the allergic reaction. +++ Potent inhibitor (>85% inhibition), ++ Moderate inhibitor (> 70% inhibition), + Poor inhibitor (< 50% inhibition), - No inhibition.

EXAMPLE 4
TESTING OF THE EFFECTS OF THE TREATMENT
OF THE PRESENT INVENTION *IN VIVO*

5 The ability of various peptides to block the release of histamine secretion *in vivo* was tested on the skin of rats by using compound 48/80 as the allergen. Peptide 2, and the succinylated derivative thereof, were shown to effectively block the allergic response by preventing the release of histamine from mast cells *in vivo*. The experimental method was as follows.

10 **MATERIALS AND METHODS**

15 The hair of the abdominal area of C.R rats was carefully removed with an electric clipper and a depilatory cream. In each animal the abdominal area was divided to six equal zones that were marked by pen. Each zone was either subjected to peptide treatment or served as a control. In the first set of experiments, the peptide was topically applied as follows: 36 μ l of peptide solution at the indicated concentration (dissolved in 72% DMSO in saline) was applied on desired abdominal area. In the second set of experiments, the peptide was injected intradermally as follows: 20 μ l of peptide solution at different concentrations (dissolved in 10% DMSO in saline) was injected intradermally to an indicated abdominal area using a 27-gauge sterile needle.

20 Skin tests were performed 0.5, 1 or 2 hours following application of the peptide. Skin tests were performed by injecting intradermally 20 μ l of the allergen (0.1 mg/ml compound 48/80 dissolved in saline) or saline alone, into the center of each marked area on the abdominal skin using a 27-gauge sterile needle. The allergic response was
25 monitored by outlining with a marker the wheals which developed in response to allergen or saline treatment.

To quantitate the skin test results, the marker signs were transferred onto paper with scotch tape. The areas of the wheals were outlined and calculated by a computerized planimeter (Hewlett-Packard), as previously described (Sussman et al., 1982).

5 RESULTS

The area of the wheals which developed in response to topical application of peptide 2 followed by compound 48/80 or saline injection is given in Table 2, with the net wheal area given in Table 3. These results demonstrate that the size of the wheals which developed after saline injection range between 72-93 mm² while the size of the wheals which developed after the injection of compound 48/80 range between 114-134 mm², demonstrating a significant allergic response induced by intradermal injection of compound 48/80 as compared to saline. The wheals which developed following the application of peptide 2 and saline injection, without compound 48/80, were slightly smaller than the wheals developed following no peptide application (Table 3A). These results demonstrate that topical application of peptide 2 by itself exerts no stimulatory effect on the cutaneous allergic reactions.

Comparing the net allergic reaction, which is the wheal area induced by saline injection subtracted from the wheal area induced by the injection of compound 48/80 injection, reveal that topical application of 350 micrograms of peptide 2 reduced compound 48/80-induced allergic reaction from a net wheal area of 41-42 mm² to a net wheal area of 9-12 mm² (Table 3B).

These results further reinforce the *in vitro* results, demonstrating that peptide 2 has the potential to also block allergic reactions *in vivo*, such as the cutaneous allergic reactions. The area of the wheals which developed in response to intradermal injection of peptide 2 followed by compound 48/80 or saline injection is given in Table 4, with the net

wheal area given in Table 5. The wheals, which developed following the injection of peptide 2 and saline, without compound 48/80, were similar to the wheals developed following no peptide application (Table 4, 5A). These results demonstrate that intradermal injection of peptide 2 by itself exerts hardly any stimulatory effect on the cutaneous allergic reactions.

Comparing the net allergic reaction, which is the wheal area induced by saline injection subtracted from the wheal area induced by the injection of compound 48/80, reveal that intradermal injection of 20 µg of peptide 2 already reduced compound 48/80-induced allergic reaction (Table 5B), while a higher dose of 200 µg of the peptide, increased the inhibition effect (Table 5B).

Table 2: Wheal areas (mm²) in response to topical application of peptide 2 followed by injection of saline or compound 48/80.

Peptide application Skin test	Peptide concentration		
	0	1 mg/ml	10 mg/ml
Saline injection (control)	93.52 ^a	84.64 ^a	85.24 ^a
	72.39 ^b	66.91 ^b	66.40 ^b
compound 48/80 injection	134.50 ^a	126.00 ^a	94.46 ^a
	114.80 ^b	106.70 ^b	85.48 ^b

^a Animal a - Skin tests were performed 1 hour after application of the peptide.

^b Animal b - Skin tests were performed 2 hours after application of the peptide.

Table 3: Net wheal areas (mm²) in response to topical application of peptide 2

A: Effect of Peptide (alone)

Peptide application Animal	Peptide concentration	
	1 mg/ml	10 mg/ml
A*	-8.8	-8.3
B**	-5.5	-6.0

B: Effect of Peptide on 48/80 induced weal response

Peptide application Animal	Peptide concentration		
	0	1 mg/ml	10 mg/ml
A*	41.0	41.4	9.2
B**	42.4	39.8	19.1

* Animal A - Skin tests were performed 1 hour after application of the peptide.

** Animal B - Skin tests were performed 1 hour after application of the peptide.

Table 4: Wheal areas (mm²) in response to intradermal injection of peptide 2 followed by injection of saline or compound 48/80.

Peptide concentration Skin test	0	1 mg/ml	10 mg/ml
Saline injection (control)	62.49 ^a 112.2 ^b 60.81 ^c	65.78 ^a 119.2 ^b 77.31 ^c	60.81 ^a 102.3 ^b 57.81 ^c
compound 48/80 injection	175.3 ^a 175.3 ^b 117.6 ^c	141.5 ^a 120.8 ^b 118.5 ^c	82.06 ^a 107.6 ^b 72.77 ^c

- 5 ^a Animal a - Skin tests were performed 0.5 hour after injection of the peptide.
^b Animal b - Skin tests were performed 1 hour after injection of the peptide.
^c Animal c - Skin tests were performed 2 hours after injection of the peptide.

Table 5: Net wheal areas (mm²) in response to intradermal injection of peptide 2

A: Effect of Peptide (alone)

Peptide concentration Animal	1 mg/ml	10 mg/ml
A*	3.29	-1.68
B**	7.0	-9.9
C***	16.5	-3.0

B: Effect of Peptide on compound 48/80 induced weal response

Peptide concentration Animal	0	1 mg/ml	10 mg/ml
A*	112.8	75.7	21.3
B**	63.1	1.6	5.3
C***	56.8	41.2	15

* Animal A - Skin tests were performed 0.5 hour after injection of the peptide.

10 ** Animal B - Skin tests were performed 1 hour after injection of the peptide.

*** Animal C - Skin tests were performed 2 hours after injection of the peptide.

Additional skin tests were performed on rats, using compound 48/80 as the allergen, to test the ability of peptide 2, peptide 2-Suc, and peptide 2-Cyc, to block allergic reactions *in vivo*. The abdominal skin of the rats was subjected to peptide or vehicle

treatment (intradermal injection). The allergic response was then induced by intradermal injection of compound 48/80 (0.1 mg/ml) at various times following the application of the peptide. A representative experiment is demonstrated in Figure 14. Calculating the areas of the wheals, which developed, quantitated the allergic response

5 Table 6 presents the mean areas of the wheals, which developed in response to intradermal injection of peptide 2, followed by either compound 48/80 or saline injection applied after 0.5h. or 1h. These results demonstrate that intradermal injection of peptide 2 has the potential to block compound 48/80 induced allergic reaction *in vivo*. Peptide 2 reduced the wheal area in a dose dependent manner, reaching significant inhibition at
10 doses of 20 and 200 µg peptide (injection of 20 µl from a stock solution of 1 mg/ml or 10 mg/ml). Significant inhibition was detected at different timing (1 hour or 2 hours before the allergic induction; Wheal areas differ significantly from the control group, $P < 0.01$, student's T-test).

Table 7 presents the mean areas of the wheals, which developed in response to
15 intradermal injection of peptide 2-Suc, followed by either compound 48/80 or saline injection applied after 0.5h. or 1h. These results demonstrate that intradermal injection of peptide 2-Suc blocks the allergic reaction induced by compound 48/80 *in vivo*. However peptide 2 Suc was less effective than peptide 2 in the *in vivo* system.

Peptide 2-Suc significantly reduced the wheal when applied 0.5 hour before the
20 allergic reaction, at a dose of 200 µg peptide. A lower dose or longer timing (1 hour before the allergic induction) had no effect.

Table 8 presents the mean areas of the wheals, which developed in response to intradermal injection of peptide 2-Cyc, followed by either compound 48/80 or saline injection applied after 0.5h. or 1h. These results demonstrate that intradermal injection of
25 peptide 2-Cyc blocks the allergic reaction induced by compound 48/80 *in vivo*. However,

peptide 2-Cyc is also less effective than peptide 2 in the *in vivo* system, demonstrating a significant decrease in wheal area when applied 0.5 hour before the allergic induction, at a dose of 200 µg peptide. A lower dose or longer timing (1 hour before the allergic induction) had no effect.

5 Noteworthy, intradermal injection of each peptide alone, exerted no stimulatory effect on the cutaneous allergic reactions, thus indicating that each compound by itself is not allergic (see Tables 5, 6 and 7).

10 **Table 6: Mean Wheal Area (mm²±STD) in Response to Intradermal Injection of Peptide 2 followed by compound 48/80.**

A. Intradermal injection of Peptide 2, one half hour before allergic induction

	Peptide Concentration (mg/ml)		
	0	1	10
Vehicle	62.7 ±9.6(n=7)	60.7 ±19.3(n=7)	54.8 ±11(n=5)
Compound 48/80	131.3 ±39.0(n=7)	80.6 ±16.3*(n=7)	74.9 ±15.0*(n=5)

15 **B. Intradermal injection of Peptide 2, 1 hour before allergic induction**

	Peptide Concentration (mg/ml)		
	0	1	10
Vehicle	65.7 ±18.5(n=5)	52.3 ±11.1(n=5)	50.6 ±7.4(n=5)
Compound 48/80	110.7 ±29.6(n=5)	79.8 ±22.2*(n=5)	69.3 ±11.7*(n=5)

* p< 0.01 as compared to positive control group (Compound 48/80) All vehicle groups are significantly different from the positive control groups (Compound 48/80, p<0.0.1)

Table 7: Mean Wheal Area (mm²±STD) in Response to Intradermal Injection of Peptide 2-Suc followed by compound 48/80.

A. Intradermal injection of Peptide 2-Suc, 0.5 hour before allergic induction

	Peptide Concentration (mg/ml)		
	0	1	10
Vehicle	56.2 ±19.5 (n=11)	56.8 ±24.1 (n=11)	57.2 ±21.7 (n=10)
Compound 48/80	109.7 ±44.9 (n=11)	93.4 ±32.0 (n=11)	73.8 ±28.7* (n=10)

B. Intradermal injection of Peptide 2-Suc, 1 hour before allergic induction

	Peptide Concentration (mg/ml)		
	0	1	10
Vehicle	51.9 ±23.4 (n=12)	57.7 ±23.2 (n=12)	54.3 ±25.8 (n=12)
Compound 48/80	98.9 ±30.4 (n=12)	89.3 ±30.1 (n=12)	78.1 ±28.3 (n=12)

* p< 0.05 as compared to positive control group (Compound 48/80) All vehicle groups are significantly different from the positive control groups (Compound 48/80, p<0.0.1)

Table 8: Mean Wheal Area (mm²±STD) in Response to Intradermal Injection of Peptide 2-Cyc followed by compound 48/80.

A. Intradermal injection of Peptide 2-Cyc, 0.5 hour before allergic induction

	Peptide Concentration (mg/ml)		
	0	1	10
Vehicle	68.9 ±37.1 (n=5)	61.4 ±30.9 (n=5)	58.8 ±29.6 (n=5)
Compound 48/80	147.3 ±36.0 (n=5)	104.4 ±45.8 (n=5)	82.6 ±50.6* (n=5)

B. Intradermal injection of Peptide 2-Cyc, 1 hour before allergic induction

	Peptide Concentration (mg/ml)		
	0	1	10
Vehicle	47.3 ±12.9 (n=6)	54.6 ±12.1 (n=6)	45.0 ±7.9 (n=6)
Compound 48/80	101.0 ±34.6 (n=6)	84.5 ±29.7 (n=6)	75.3 ±28.4 (n=6)

* p< 0.05 as compared to positive control group (Compound 48/80) All vehicle groups are significantly different from the positive control groups (Compound 48/80, p<0.0.1).

EXAMPLE 5
METHODS AND COMPOSITIONS FOR ADMINISTRATION

The peptides of the present invention, and their homologues or related compounds, hereinafter referred to as the "therapeutic agents of the present invention", can be administered to a subject by various ways, which are well known in the art. Hereinafter, the term "therapeutic agent" includes a peptide as previously defined, in particular peptide 2 and/or homologues, analogues or mimetics thereof, such as the succinylated derivative thereof, or any biologically active substance having a substantially similar effect as previously defined.

Hereinafter, the term "subject" refers to the human or lower animal to whom the therapeutic agent is administered. For example, administration may be done topically (including ophthalmically, vaginally, rectally, intranasally and by inhalation), orally, or parenterally, for example by intravenous drip or intraperitoneal, subcutaneous, or intramuscular injection.

Formulations for topical administration may include but are not limited to lotions, ointments, gels, creams, suppositories, drops, liquids, sprays and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.

Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, sachets, capsules or tablets. Thickeners, diluents, flavorings, dispersing aids, emulsifiers or binders may be desirable.

Formulations for parenteral administration may include but are not limited to sterile aqueous solutions which may also contain buffers, diluents and other suitable additives.

Dosing is dependent on the severity of the symptoms and on the responsiveness of the subject to the therapeutic agent. Persons of ordinary skill in the art can easily determine

optimum dosages, dosing methodologies and repetition rates.

EXAMPLE 6
METHOD OF TREATMENT OF ALLERGIC CONDITIONS

5 As noted above, the therapeutic agents of the present invention have been shown to be effective inhibitors of the allergic process by blocking mast cell degranulation, thereby preventing and/or alleviating an allergic condition. The following example is an illustration only of a method of treating an allergic condition with the therapeutic agent of the present invention, and is not intended to be limiting.

10 The method includes the step of administering a therapeutic agent, in a pharmaceutically acceptable carrier as described in Example 3 above, to a subject to be treated. The therapeutic agent is administered according to an effective dosing methodology, preferably until a predefined endpoint is reached, such as the absence of a symptom of the allergic condition in the subject, or the prevention of the appearance of
15 such a symptom in the subject.

Allergic conditions for which the therapeutic agents of the present invention are useful include, but are not limited to, nasal allergy, irritation or allergic reactions in the eyes, allergic reactions in the skin including any type of allergen-induced rash or other skin irritation or inflammation, acute urticaria, psoriasis, psychogenic or allergic asthma,
20 interstitial cystitis, bowel diseases, migraines, and auto-immune diseases such as multiple sclerosis.

EXAMPLE 7
METHODS FOR MANUFACTURING
THE THERAPEUTIC COMPLEX OF THE PRESENT INVENTION

25 The therapeutic complex of the present invention can be manufactured in various

ways. For example, if the therapeutic complex includes a peptide for at least one the first segment and the second segment, or if the entire therapeutic complex is a peptide, then such a peptide could be manufactured by peptide synthetic methods which are well known in the art.

5 Alternatively, such a peptide could be produced by linking the signal sequence and the biologically active moiety through laboratory techniques for molecular biology which are well known in the art.

By way of illustration, as a non-limiting example, a recombinant fusion protein could be prepared which would feature the peptide permeabilization sequence in the N-terminus and the C-terminal moiety of $G\alpha_{it}$ or $G\alpha_{i3}$, preferably including the last 10 amino acids, for production in bacteria. For this purpose, DNA sequences coding for the desired peptides are amplified by PCR and purified. After sequence verification, these DNA sequences are ligated and cloned in an appropriate vector. The resulting recombinant plasmid is expressed in *E. coli* and

10

15 the recombinant proteins purified from bacterial extracts.

According to another preferred embodiment of the present invention, a peptide could optionally be modified. For example, the N-terminus of the peptide could be modified by succinilation, addition of a sugar residue, or addition of stearic or palmitic acid. In addition, certain amino acids of the peptide could also be modified. For

20 example, if the peptide includes a cysteine at amino acid 23, this cysteine could be replaced by another amino acid, including but not limited to, amino butyric acid, serine or other such amino acids. As another example, if the peptide includes a lysine at amino acid 17, this residue could be replaced by another amino acid, such as a neutral amino acid, or two amino acids such as a pair of glutamic acid residues. As yet another example,

25 if the peptide includes a proline at amino acid 16, this residue could be replaced by

another amino acid, such as a neutral amino acid, or two amino acids such as a pair of glutamic acid residues. Thus, the peptide could optionally be modified in order to enhance penetration into the cell or to enhance the pharmaceutical activity, for example.

- 5 It will be appreciated that the above descriptions are intended only to serve as examples, and that many other embodiments are possible within the spirit and the scope of the present invention, as defined in the claims which follow.

References

- 10 Aridor M., Traub L.M. and Sagi-Eisenberg R. (1990). Exocytosis in mast cells by basic secretagogues: Evidence for direct activation of GTP-binding proteins. *J. Cell Biol.* 111:909-917.
- 15 Aridor M. and Sagi-Eisenberg R. (1990). Neomycin is a potent secretagogue of mast cells that directly activates a GTP-binding protein involved in. *J. Cell Biol.* 111:2885-2891.
- Aridor M., Rajmlevich G., Beaven M.A. and Sagi-Eisenberg R. (1993). Activation of exocytosis by the heterotrimeric G protein G_{i3} . *Science* 262:1569-1572.
- 20 Bienenstock J., Tomioka M., Stead R., Ernst P., Jordana M., Gauldie J., Dolovich J. and Denburg J. (1987). Mast cell involvement in various inflammatory processes. *Am. Rev. Respir. Dis.* 135:S5-S8.
- 25 Chahdi A., Mousli M. and Landry Y. (1998). Substance P-related inhibitors of mast cell exocytosis act on G-proteins or on the cell surface. *Eur. J. Pharmacol.* 341,329-335.
- Columbo M., Horowitz E.M., Kagey-Sobotka A. and Lichtenstein L.M. (1996). Substance P activates the release of histamine from human skin mast cells through a pertussis toxin-sensitive and protein kinase C-dependent mechanism. *Clin. Immunol. Immunop.* 81,68-73.
- 30 Devillier P., Regoli D., Asseraf A., Descours B., Marsac J. and Renoux M. (1986). Histamine release and local responses of rat and human skin to substance P and other mammalian tachykinins. *Pharmacology* 32:340-347.
- 35 Emadi-Khiav B., Mousli M., Bronner C. and Landry Y. (1995). Human and rat cutaneous mast cells: involvement of a G protein in the response to peptidergic stimuli. *Eur. J. Pharmacol.* 272,97-102.
- 40 Ennis M., Pearce F.L. and Weston P.M. (1980). Some studies on the release of histamine from mast cells stimulated with polylysine. *Br. J. Pharmacol.* 70:329-334.
- Foreman J.C. (1987a). Neuropeptides and the pathogenesis of allergy. *Allergy* 42:1-11.

Foreman J.C. (1987b). Substance P and calcitonin gene-related peptide: Effect on mast cells and in human skin. *Int. Archs. Allergy appl. Immun.* 82:366-371.

Goldberg A., Korzets Z., Bernheim J. And Mekori Y.A. (1991). Cutaneous responses to histamine, compound 48/80 and codeine in patients with chronic renal failure. *Annals Allergy* 67 :525-528.

Gomperts B.D., Churcher Y., Koffer A., Lillie T.H.W., Tatham P.E.R. and Whalley T. D (1991). Intracellular mechanisms regulating exocytotic secretion in mast cells. *Int. Arch. Allergy Appl. Immunol.* 94:38-46.

Hawiger J. 1997. Cellular import of functional peptides to block intracellular signaling. *Curr. Opin. Immunol.* 9: 189-194.

Kivity S., Sneh E., Greif J., Topilsky M. and Mekori Y.A. (1988). The effect of food and exercise on the skin response to compound 48/80 in patients with food-associated exercise-induced urticaria-angioedema. *J. Allergy Clin. Immunol.* 81:1155-1158.

Lichtenstein L.M (1993). Allergy and the immune system. *Scientific American* 269: 116-124.

Lin Y.Z., Yau S.Y., Veach R.A., Torgerson T.R and Hawiger J. 1995. Inhibition of nuclear translocation of transcription factor NF-kB by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. *J.Biol.Chem.* 270:14255-14258.

Mousli M., Hugli T.E. Landry Y. and Bronner C. (1994). Peptidergic pathway in human skin and rat peritoneal mast cell activation. *Immunopharmacol.* 27:1-11.

Pearce F.L., Kassessinoff T.A., Liu W.L. (1989). Characteristics of histamine secretion induced by neuropeptides: Implications for the relevance of peptide-mast cell interactions in allergy and inflammation. *Int. Arch. Allergy Appl. Immunol.* 88:129-131.

Prochiantz A. 1996. Getting hydrophilic compounds into cells: lessons from homeopeptides. *Curr. Opin. Neurobiol.* 6:629-634.

Sagi-Eisenberg R. (1993). Signal-transmission pathways in mast cell exocytosis. In: *Immunopharmacology of mast cells and Basophils.*

Sussman G.L., Harvey R.P. and Schocket A.L (1982). Evaluation of skin test response using two techniques of measurement. *Ann. Allergy* 48:75-77.

Theoharides T.C. (1996). The mast cell: a neuroimmunoendocrine master player. *Int. J. Tissue React.* 18:1-21.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Eisenberg and Raz
SERIAL NO: 10/009,809 INTERNATIONAL PCT/IL00/00346
APPLICATION NO :
I.A. FILING DATE: 06/14/2000 PRIORITY DATE : 06/17/1999
FOR: NOVEL ANTI-ALLERGIC AGENTS


April 26, 2002
Boston, Massachusetts

Box PCT
Commissioner for Patents
Washington, D.C. 20231

STATEMENT IN SUPPORT OF COMPUTER READABLE
FORM SUBMISSION UNDER 37 C.F.R. § 1.821(f)

I hereby state that the content of the paper and computer readable forms of the Sequence Listing, submitted in the above-identified application in accordance with 37 C.F.R. § 1.821(c) and 1.821(e), respectively, are the same. No new matter is added at this time.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Barry J. Marenberg, Reg. No. 40,715
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

SEQUENCE LISTING

<110> Eisenberg, Ronit
Raz, Tamar

<120> Novel Anti-Allergic Agents

<130> 24025-501 NATL

<140> 10/009,809

<141> 2000-06-14

<150> PCT/IL00/00346

<151> 2000-06-14

<150> IL 130526

<151> 1999-06-17

<160> 21

<170> PatentIn Ver. 2.1

<210> 1

<211> 10

<212> PRT

<213> Homo sapiens

<400> 1

Lys Asn Asn Leu Lys Glu Cys Gly Leu Tyr
1 5 10

<210> 2

<211> 10

<212> PRT

<213> Homo sapiens

<400> 2

Lys Asn Asn Leu Lys Asp Cys Gly Leu Phe
1 5 10

<210> 3

<211> 16

<212> PRT

<213> Homo sapiens

<400> 3

Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Ala Pro
1 5 10 15

<210> 4

<211> 15

<212> PRT

<213> Homo sapiens

<400> 4

Val Thr Val Leu Ala Leu Gly Ala Leu Ala Gly Val Gly Val Gly
1 5 10 15

<210> 5

<211> 16

<212> PRT

<213> Drosophila acanthoptera

<400> 5

Arg Gln Pro Lys Ile Trp Phe Pro Asn Arg Arg Lys Pro Trp Lys Lys
1 5 10 15

<210> 6

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 6

Val Thr Val Leu Ala Leu Gly Ala Leu Ala Gly Val Gly Val Gly Lys
1 5 10 15

Asn Asn Leu Lys Glu Cys Gly Leu Tyr
20 25

<210> 7

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 7

Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro
1 5 10 15

Lys Asn Asn Leu Lys Glu Cys Gly Leu Tyr
20 25

<210> 8

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<220>
<221> VARIANT
<222> (1)..(26)
<223> N-terminal amino acid is succunylated

<400> 8
Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro
1 5 10 15
Lys Asn Asn Leu Lys Glu Cys Gly Leu Tyr
20 25

<210> 9
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Peptide

<220>
<221> VARIANT
<222> (7)
<223> A bond exists between the side chain of Lys and
the C-terminus of the peptide.

<400> 9
Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro
1 5 10 15
Lys Asn Asn Leu Lys Glu Cys Gly Leu Tyr
20 25

<210> 10
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 10
Arg Gln Pro Lys Ile Trp Phe Pro Asn Arg Arg Lys Pro Trp Lys Lys
1 5 10 15
Lys Asn Asn Leu Lys Glu Cys Gly Leu Tyr
20 25

<210> 11
<211> 25
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 11

Val Thr Val Leu Ala Leu Gly Ala Leu Ala Gly Val Gly Val Gly Lys
1 5 10 15

Glu Asn Leu Lys Asp Cys Gly Leu Phe
20 25

<210> 12

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 12

Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro
1 5 10 15

Lys Glu Asn Leu Lys Asp Cys Gly Leu Phe
20 25

<210> 13

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 13

Arg Gln Pro Lys Ile Trp Phe Pro Asn Arg Arg Lys Pro Trp Lys Lys
1 5 10 15

Lys Glu Asn Leu Lys Asp Cys Gly Leu Phe
20 25

<210> 14

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 14

Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro
1 5 10 15

Lys Asn Asn Leu Lys Asp Cys Gly Leu Phe
20 25

<210> 15

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<220>

<221> VARIANT

<222> (1)..(26)

<223> N-terminal amino acid is succinylated

<400> 15

Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro
1 5 10 15

Lys Glu Asn Leu Lys Asp Cys Gly Leu Phe
20 25

<210> 16

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 16

Lys Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala
1 5 10 15

Pro Lys Asn Asn Leu Lys Asp Cys Gly Leu Phe
20 25

<210> 17

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 17

Lys Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala
 1 5 10 15

Pro Lys Asn Asn Leu Lys Glu Cys Gly Leu Tyr
 20 25

<210> 18
 <211> 23
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 Peptide

<400> 18
 Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro
 1 5 10 15

Leu Lys Glu Cys Gly Leu Tyr
 20

<210> 19
 <211> 23
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 Peptide

<400> 19
 Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro
 1 5 10 15

Leu Lys Asp Cys Gly Leu Phe
 20

<210> 20
 <211> 26
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 Peptide

<400> 20
 Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro
 1 5 10 15

Lys Asn Asn Leu Lys Glu Ser Gly Leu Tyr
 20 25

1990	1991	1992
1993	1994	1995
1996	1997	1998
1999	2000	2001
2002	2003	2004
2005	2006	2007
2008	2009	2010
2011	2012	2013
2014	2015	2016
2017	2018	2019
2020	2021	2022
2023	2024	2025
2026	2027	2028
2029	2030	2031
2032	2033	2034
2035	2036	2037
2038	2039	2040
2041	2042	2043
2044	2045	2046
2047	2048	2049
2050	2051	2052
2053	2054	2055
2056	2057	2058
2059	2060	2061
2062	2063	2064
2065	2066	2067
2068	2069	2070
2071	2072	2073
2074	2075	2076
2077	2078	2079
2080	2081	2082
2083	2084	2085
2086	2087	2088
2089	2090	2091
2092	2093	2094
2095	2096	2097
2098	2099	2100
2101	2102	2103
2104	2105	2106
2107	2108	2109
2110	2111	2112
2113	2114	2115
2116	2117	2118
2119	2120	2121
2122	2123	2124
2125	2126	2127
2128	2129	2130
2131	2132	2133
2134	2135	2136
2137	2138	2139
2140	2141	2142
2143	2144	2145
2146	2147	2148
2149	2150	2151
2152	2153	2154
2155	2156	2157
2158	2159	2160
2161	2162	2163
2164	2165	2166
2167	2168	2169
2170	2171	2172
2173	2174	2175
2176	2177	2178
2179	2180	2181
2182	2183	2184
2185	2186	2187
2188	2189	2190
2191	2192	2193
2194	2195	2196
2197	2198	2199
2200	2201	2202
2203	2204	2205
2206	2207	2208
2209	2210	2211
2212	2213	2214
2215	2216	2217
2218	2219	2220
2221	2222	2223
2224	2225	2226
2227	2228	2229
2230	2231	2232
2233	2234	2235
2236	2237	2238
2239	2240	2241
2242	2243	2244
2245	2246	2247
2248	2249	2250
2251	2252	2253
2254	2255	2256
2257	2258	2259
2260	2261	2262
2263	2264	2265
2266	2267	2268
2269	2270	2271
2272	2273	2274
2275	2276	2277
2278	2279	2280
2281	2282	2283
2284	2285	2286
2287	2288	2289
2290	2291	2292
2293	2294	2295
2296	2297	2298
2299	2300	2301
2302	2303	2304
2305	2306	2307
2308	2309	2310
2311	2312	2313
2314	2315	2316
2317	2318	2319
2320	2321	2322
2323	2324	2325
2326	2327	2328
2329	2330	2331
2332	2333	2334
2335	2336	2337
2338	2339	2340
2341	2342	2343
2344	2345	2346
2347	2348	2349
2350	2351	2352
2353	2354	2355
2356	2357	2358
2359	2360	2361
2362	2363	2364
2365	2366	2367
2368	2369	2370
2371	2372	2

<223> Description of Artificial Sequence: Synthetic Peptide

<221> VARIANT

<223> Ala in D/L configuration

Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro
1 5 10 15

Lys Asn Asn Leu Lys Glu Cys Gly Leu Tyr
20 25

Art. 34

10/009809

PCT/IL00/00346

IPEA/US 02 MAY 2001

CLAIMS

WHAT IS CLAIMED IS:

531 Rec'd PCT 07 DEC 2001

1. An anti-allergic complex molecule, having at least a first segment competent for importation of said molecule into mast cells in vivo, and a second segment for having an anti-allergic effect within said mast cells, said first segment being joined to said second segment through a linker, whereby the complex molecule is capable of exerting its anti-allergic effect in vivo.
2. The complex molecule of claim 1, wherein said second segment has said anti-allergic effect by at least significantly reducing degranulation of said mast cells.
3. The complex molecule of claim 2, wherein said second segment is selected from the group consisting of a peptide, a peptidomimetic and a polypeptide.
4. The complex molecule of claim 3, wherein said second segment is a peptide.
5. The complex molecule of claim 4, wherein said first segment is a peptide.
6. The complex molecule of claim 5, wherein said linker is a covalent bond.
7. The complex molecule of claim 6, wherein said covalent bond is a peptide bond.
8. The complex molecule of claim 7, wherein said molecule is a peptide

20090909 042600

Ag-34

taken from the C terminal sequence of Gxi₃.

9. The complex molecule of claim 8, wherein said peptide has an amino acid sequence AAVALLPAVLLALLAPKNNLKECGLY, and cyclic derivatives thereof.

10. The complex molecule of claim 7, wherein said molecule is a peptide taken from the C terminal sequence of Gxi.

11. The complex molecule of claim 10, wherein said molecule is a peptide having an amino acid sequence AAVALLPAVLLALLAPKENLKDCGLF, and cyclic derivatives thereof.

12. A composition for treating an allergic condition in a subject, comprising a pharmaceutically effective amount of a molecule having at least a first segment competent for importation of said molecule into mast cells in vivo, and a second segment for having an anti-allergic effect within said mast cells, said first segment being joined to said second segment through a linker, whereby the complex molecule is capable of exerting its anti-allergic effect in vivo.

13. The composition of claim 12, wherein the allergenic condition is selected from the group consisting of nasal allergy, an allergic reaction in an eye of the subject, an allergic reaction in the skin of the subject, acute urticaria, psoriasis, psychogenic or allergic asthma, interstitial cystitis, bowel diseases, migraines, and multiple sclerosis.

IPEA/VUS 02 MAY 2001

- Art. 3.4
14. The composition of claim 12, further comprising a pharmaceutically acceptable diluent or carrier.
15. The composition of claim 14, in a dosage form suitable for topical administration to the eye, the skin or to the mucous membrane of a subject.
16. The composition of claim 14, in a dosage form suitable for administration by inhalation or intranasal administration.
17. The composition of claim 14, in a dosage form suitable for oral or parenteral systemic administration.
18. The composition of claim 13, wherein said second segment has said anti-allergic effect by at least significantly reducing degranulation of said mast cells.
19. The composition of claim 18, wherein said second segment is selected from the group consisting of a peptide, a peptidomimetic and a polypeptide.
20. The composition of claim 19, wherein said second segment is a peptide.
21. The composition of claim 20, wherein said first segment is a peptide.
22. The composition of claim 21, wherein said linker is a covalent bond.
23. The composition of claim 22, wherein said covalent bond is a peptide

bond.

24. The composition of claim 23, wherein said second segment is a peptide taken from the C terminal sequence of G α ₁₃.

25. The composition of claim 24, wherein said molecule is a peptide having an amino acid sequence AAVALLPAVLLALLAPKNNLKECGLY, and cyclic derivatives thereof.

26. The composition of claim 23, wherein said second segment is a peptide taken from the C terminal sequence of G α _t.

27. The composition of claim 26, wherein said molecule is a peptide having an amino acid sequence AAVALLPAVLLALLAPKENLKDCGLF, and cyclic derivatives thereof.

28. The composition of claim 27, wherein said therapeutic agent further comprises a second molecule, said second molecule being a peptide having an amino acid sequence AAVALLPAVLLALLAPKNNLKECGLY.

29. The composition of claim 20 wherein said molecule is a derivatized peptide having an amino acid sequence Succinyl-AAVALLPAVLLALLAPKNNLKECGLY.

30. A method for treating an allergic condition in a subject, comprising

administering a pharmaceutically effective amount of a therapeutic agent to the subject, said therapeutic agent comprising a molecule having at least a first segment competent for importation of said molecule into mast cells in vivo, and a second segment for having an anti-allergic effect within said mast cells, said first segment being joined to said second segment through a linker, whereby the complex molecule is capable of exerting its anti-allergic effect in vivo.

31. The method of claim 30, wherein the allergic condition is selected from the group consisting of nasal allergy, an allergic reaction in an eye of the subject, an allergic reactions in the skin of the subject, acute urticaria, psoriasis, psychogenic or allergic asthma, interstitial cystitis, bowel diseases, migraines, and multiple sclerosis.

32. The method of claim 31, wherein administration of said therapeutic agent is performed by topical administration.

33. The method of claim 32, wherein said topical administration is to the eye, the skin or to a mucous membrane of the subject.

34. The method of claim 33, wherein administration of said therapeutic agent is performed by inhalation or intranasal administration.

35. The method of claim 34, wherein administration of said therapeutic agent is performed by oral or systemic parenteral administration.

36. The method of claim 32, wherein said second segment has said anti-

Art. 34

allergic effect by at least significantly reducing degranulation of said mast cells.

37. The method of claim 36, wherein said second segment is selected from the group consisting of a peptide, a peptidomimetic, or a polypeptide.
38. The method of claim 37, wherein said second segment is a peptide.
39. The method of claim 38, wherein said first segment is a peptide.
40. The method of claim 39, wherein said linker is a covalent bond.
41. The method of claim 40, wherein said covalent bond is a peptide bond.
42. The method of claim 41, wherein said second segment is a peptide taken from the C terminal sequence of G α _{i3}.
43. The method of claim 42, wherein said molecule is a peptide having an amino acid sequence AAVALLPAVLLALLAPKNNLKECGLY, and cyclic derivatives thereof.
44. The method of claim 41, wherein said second segment is a peptide taken from the C terminal sequence of G α t
45. The method of claim 44, wherein said molecule is a peptide having an amino acid sequence AAVALLPAVLLALLAPKENLKDCGLF.

Art. 34

46. The method of claim 39, wherein said therapeutic agent further comprises a second molecule, said second molecule being a peptide having an amino acid sequence AAVALLPAVLLALLAPKNNLKECGLY.

47. The method of claim 31, wherein said molecule is a peptide having an amino acid sequence Succinyl- AAVALLPAVLLALLAPKNNLKECGLY.

48. The complex molecule of claim 8, further comprising cyclization between lysine at position 17 and the C terminus of the peptide.

49. The composition of claim 25 wherein said molecule further comprises cyclization between lysine at position 17 and the C terminus of the peptide.

50. The method of claim 31 wherein the molecule further comprises cyclization between lysine at position 17 and the C terminus of the peptide.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 December 2000 (28.12.2000)

(10) International Publication Number
WO 00/78346 A1

PCT

- (51) **International Patent Classification⁷:** A61K 39/385
- (21) **International Application Number:** PCT/IL00/00346
- (22) **International Filing Date:** 14 June 2000 (14.06.2000)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
130526 17 June 1999 (17.06.1999) IL
- (71) **Applicant (for all designated States except US):** ALLER-
GENE LTD. [IL/IL]; 2A Katzir Street, Tel Hashomer,
52656 Ramat Gan (IL).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** EISENBERG,
Ronit [IL/IL]; 6 Lotus Street, 74047 Ness-Ziona (IL).
RAZ, Tamar [IL/IL]; 72/12 He-Beiyar Street, 48056 Rosh
Haayin (IL).
- (74) **Agent:** WEBB, Cynthia; P.O. Box 2189, 76122 Rehovot
(IL).
- (81) **Designated States (national):** AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE,
DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO,
NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) **Designated States (regional):** ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— With international search report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *With international search report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL ANTI-ALLERGIC AGENTS

(57) Abstract: The present invention discloses novel complex molecules useful as anti-allergic agents. These complex molecules include in particular, peptidic or peptidomimetic molecules, having a first segment which is competent for cell penetration and a second segment which is able to reduce or abolish mast cell degranulation, and in particular to reduce or abolish allergy mediators such as histamine secretion from mast cells. Specific examples of peptides with the desired activity are disclosed.

[illegible]

WO 00/78346 A1

Figure 1:




Figure 2:




Figure 3:




Figure 4:





Figure 5:


Figure 6:


Figure 7:


Figure 8:


Figure 9:

Figure 10:




Figure 11:





Figure 12:




Figure 13:




Figure 14:



My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a utility patent is sought on the invention entitled:

NOVEL ANTI-ALLERGIC AGENTS

the specification of which:

- ☒ was filed on 14 June 2000 as PCT Application No. PCT/IL00/00346 and nationalized in the United States as Serial No. 10/009,809, bearing Attorney Docket No. 24025-501.
- ☐ is attached hereto.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

- ☐ I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application designating at least one country other than the United States listed below and have also identified below any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

[illegible]

- ☒ I hereby claim the benefit under Title 35, United States Code, § 119(e) or §120 of any United States application(s), or §365(c) of any PCT International application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

Application No. (U.S.S.N.)	Filing Date (dd/mm/yy)	Status (Patented, Pending, Abandoned)

PCT International Applications designating the United States:

PCT International Application No.	PCT Filing Date	Status
PCT/IL00/00346	14 June 2000	Pending

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Attorney or Agent	Registration No.	Attorney or Agent	Registration No.
Kevin Ainsworth	<u>39,586</u>	Brian P. Hopkins	<u>42,669</u>
Ingrid Beattie	<u>42,306</u>	Shane Hunter	<u>41,858</u>
William Belanger	<u>40,509</u>	David E. Johnson	<u>41,874</u>
Charles E. Bell	<u>48,128</u>	Christina Karnakis	<u>45,899</u>
Naomi Biswas	<u>38,384</u>	Kristin E. Konzak	<u>44,848</u>
Bradford C. Blaise	<u>47,429</u>	Cynthia Kozakiewicz	<u>42,764</u>
Sean M. Coughlin	<u>48,593</u>	Barry Marenberg	<u>40,715</u>
David F. Crosby	<u>36,400</u>	A. Jason Mirabito	<u>28,161</u>
Christopher J. Cuneo	<u>42,450</u>	Michel Morency	<u>50,183</u>
Brett N. Dorny	<u>35,860</u>	Matthew Pavao	<u>P-50,572</u>
Marianne Downing	<u>42,870</u>	Carol H. Peters	<u>45,010</u>
Ivor R. Elrifi	<u>39,529</u>	David Poirier	<u>43,007</u>
Heidi A. Erlacher	<u>45,409</u>	Michael Renaud	<u>44,299</u>
Eugene A. Feher	<u>33,171</u>	Brian Rosenbloom	<u>41,276</u>
John M. Garvey	<u>37,833</u>	Robert J. Sayre	<u>42,124</u>
James G. Gatto	<u>32,694</u>	C. Eric Schulman	<u>43,350</u>
Richard Gervase	<u>46,725</u>	Gregory J. Sieczkiewicz	<u>48,223</u>
Matthew J. Golden	<u>35,161</u>	Janine M. Susan	<u>46,119</u>
Sonia K. Guterman	<u>44,729</u>	Howard Susser	<u>33,556</u>
John Harre	<u>37,345</u>	Nicholas P. Triano, III	<u>36,397</u>
Paul J. Hayes	<u>28,307</u>		

all of MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO PC, One Financial Center, Boston, Massachusetts 02111, as Applicant's attorneys with full power of substitution and revocation to take any and all action necessary with regard to the above-identified patent.

Please address all telephone calls to Ivor R. Elrifi at telephone number 617/348-1747.

Please address all correspondence to:


Ivor R. Elrifi
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
One Financial Center
Boston, Massachusetts 02111

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or patent issued thereon.

Ronit Sayi-Eisenberg April 18 2002
Inventor's Signature Date
Full Name of Inventor: Ronit Eisenberg
Citizenship:
Residence: Israel
Post Office Address: 6 Lotus Street, 74047 Ness-Ziona, ISRAEL ILX

Tamar Raz April 09. 2002
Inventor's Signature Date
Full Name of Inventor: Tamar Raz
Citizenship:
Residence: Israel
Post Office Address: 72/12 He-Beiyar Street, 48056 Rosh Haayin, ISRAEL ILX

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ *Scanned copy is best available.* *Figure 14 is dark.*